Cardiff Oncology shifts lead program to first-line RAS-mutated mCRC; Q2 cash burn $7.1M, runway into 2025

Cardiff Oncology, Inc.

2023-Q2 EPS reported -$0.50 revenue$191,000

New lead program in first-line RAS-mutated mCRC; interim topline data expected mid-2024; FDA agreed on endpoints for accelerated approval.
Cash $89.4M as of June 30, 2023; net cash used in operations $7.1M in Q2; runway into 2025.
Expanded Pfizer relationship: Pfizer Ignite to handle clinical execution of CRDF-004 Phase 2 trial.
Operating expenses $12.3M for Q2 2023, up from $10.5M in Q2 2022 due to higher headcount and stock-based compensation.
Upcoming milestones: mPDAC data Q3'23, SCLC data Q3'23, TNBC data Q4'23/Q1'24.

item 2.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cardiff Oncology, Inc. reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 9, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Cardiff Oncology, Inc.: Filed Certificate of Elimination to remove designations of Series B, C, D, and E Convertible Preferred Stock, returning those shares to authorized but unissued preferred stock (effective 2023-08-08).

Change: charter amendment
Effective: 2023-08-08

Exact text from the filing

On August 8, 2023, Cardiff Oncology, Inc. (the “Company”) filed, with the Secretary of State of the State of Delaware, a Certificate of Elimination (the “Certificate of Elimination”) of Series B, Series C, Series D and Series E Convertible Preferred Stock removing the designation and other references to its Series B, Series C, Series D and Series E Convertible Stock from the Company’s Amended and Restated Certificate of Incorporation, as amended.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Cardiff Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-028563

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.